We reported top-line results from our Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients. The primary endpoint of the study was the incidence of new or progressive bronchiolitis obliterans syndrome (BOS) at 180 days after RSV infection.
Read our press release Listen to our discussion of the top-line results View our presentation (449 KB PDF) View additional ALN-RSV program materialsMonthly Archives For: May 2012
May 10, 2012
Final Results from our Phase I Trial of ALN-TTR01
Today, scientists presented final results from our Phase I clinical trial of ALN-TTRo1 at the XIII International Symposium on Amyloidosis held in Groningen. Data from this study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels, including both wild-type and mutant TTR protein, in ATTR patients. Knockdown of TTR, the disease-causing protein, was found to be dose dependent, rapid, and durable after just a single dose.
View our presentation (842 KB PDF) View our release Listen to KOL, Dr. Hawkins discuss the ALN-TTR program (recorded Jan. 2012) (27.7MB MP3)May 10, 2012
ALN-TTR Historical Press Releases
Below is a list of historical press releases related to our ALN-TTR program for the treatment of transthyretin-mediated amyloidsis:
2012
July 16: Alnylam Reports Positive ALN-TTR02 Clinical Data, with Robust Knockdown of Serum Transthyretin (TTR) of up to 94% After Single Dose June 19: Alnylam Receives Orphan Drug Designation from U.S. Food & Drug Administration for ALN-TTR02, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR) June 7: Alnylam Completes Enrollment in Phase I Clinical Trial and Initiates Phase II Clinical Trial of ALN-TTR02 May 10: Alnylam Presents Final Results from a Phase I Clinical Trial of ALN-TTR01 March 19: Alnylam Initiates Phase I Clinical Study of ALN-TTR02 Jan 6: Alnylam Files Clinical Trial Application for ALN-TTR02